Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evommune Inc EVMN
$8.49
▼ -3.52%
($-0.31)
Open
$8.78
Prev Close
$8.80
Day Range
$8.33 – $8.78
52W Range
$8.69 – $33.20
Market Cap
$308.12M
Beta
0.63
EPS (TTM)
$-3.83
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2025-11-06 |
| Shares Out. | 36,020,000 |
| Website | evommune.com/ ↗ |
| Phone | 13025310855 |
| Employees | 48 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$32.2M |
| Free Cash Flow | -$91.1M |
| Total Assets | $301.9M |
| Total Liabilities | $24.4M |
| Equity | $277.6M |
About Evommune Inc
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Evommune Inc is a publicly traded company under the ticker symbol EVMN on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)
📰 Latest News for EVMN
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Evommune Consensus Price Target Decreased by 13.25% to $24.48